SHYFT Expands Real-World Evidence Solutions Empowering Life Sciences to Make Better Value-Based Decisions
February 28 2019 - 7:30AM
Business Wire
Leader in commercial and real-world data
analytics adds services, capabilities, and expertise to unlock the
value of RWE across the industry
- Enhancements to SHYFT’s capabilities
will accelerate the delivery of leading RWE products and services
to biopharma, biotech, and CRO organizations
- Addition of new services includes the
creation of an RWE solutions team, led by Bruno Lempernesse and
Aaron Galaznik, MD
SHYFT Analytics, a Medidata company (NASDAQ: MDSO), today
announced that it has significantly enhanced the real-world
evidence (RWE) components of its solution platform. This expansion
includes the appointment of key leadership positions that allow the
company to cater to a broader range of life science organizations,
including large biopharma companies, emerging biotechs, and
contract research organizations (CROs).
The expanded RWE solutions team will serve as a dedicated
resource and will focus solely on supporting the life science
industry’s data analytics and evidence generation needs. SHYFT’s
comprehensive RWE offering combines its groundbreaking QUANTUM RWE
technology with decades of in-house data analytics expertise,
advanced data science capabilities, and a full-suite of RWE
consulting services that allow SHYFT to cater to life science
organizations with varying levels of real-world experience. These
services include, but are not limited to data source
identification, analytics best practices consulting, and full
outcomes study generation.
Leading the strategy behind this initiative will be Bruno
Lempernesse and Aaron Galaznik, MD – two recent additions to SHYFT
who add more than thirty years of experience in outcomes research
and delivery of RWE products and services to market.
As vice president and general manager of the SHYFT RWE solutions
team, Lempernesse will focus on executing and accelerating the
evidence generation strategies of SHYFT’s biopharma and CRO
partners. Prior to joining SHYFT, Lempernesse was the CEO of
Inflexxion, an industry leader for clinical assessment and RWE
related to substance use and drug abuse.
Galaznik, as head of research, will lead a team working
hand-in-hand with customers and partners to execute and inform
research strategy, and support the growing RWE needs of the
industry. Prior, he served in leadership roles at Takeda and Pfizer
developing and executing real-world data initiatives.
“SHYFT’s QUANTUM platform represents truly disruptive technology
that fulfills the substantial value and evidence needs of the life
science industry with unprecedented efficiency,” Lempernesse said.
“I’m thrilled to be a part of a team driving market-wide
transformation.”
“SHYFT spent several years developing ground-breaking software
for real-world evidence and delivering value to life science
partners,” said Zack King, president of SHYFT and executive vice
president, Medidata. “We are incredibly fortunate to add Bruno and
Aaron to our expert RWE solutions team to execute some of our
customers’ most important work. Their combined experience and
leadership will ensure that SHYFT continues to be at the forefront
of the digital transformation in healthcare.”
About SHYFT
SHYFT Analytics, a Medidata company, is the leading platform for
commercial and real-world data analytics with products designed
specifically for the pharmaceutical, biotech, and medical device
industry. SHYFT’s data analytics platform is the most efficient and
scalable way to transform massive amounts of complex healthcare
data into on-demand clinical and commercial insight. SHYFT is
headquartered in Boston with offices in San Francisco and New York
City. Learn more about SHYFT at www.shyftanalytics.com, or
follow the company on
Twitter @SHYFTAnalytics or LinkedIn.
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by the #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users every day to create hope for millions of
patients. Discover the future of life
sciences: www.medidata.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190228005172/en/
Medidata SolutionsInvestors:Betsy Frank, +1
917-522-4620bfrank@medidata.com
Media:Erik Snider, +1 646-362-2997esnider@medidata.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2024 to May 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From May 2023 to May 2024